Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,759.00-1.92%ETH$2,449.71-0.78%GOLD$4,364.00-0.98%OIL$103.08+0.59%
Smart Investors Daily
GP

NASDAQ · GPCR

Structure Therapeutics Inc.

Healthcare · Biotechnology

$41.23

Down-$1.68 (-4.07%)

Updated Sep 11, 2026, 12:41 AM

SID Score

4.3/10

Composite research score

Smart Money

53/100

Neutral

Market cap
3.88B
P/E ratio
-7.22
Dividend yield
0.00%
52-week range
$20.04 – $94.90
Volume
1.56M
Avg. volume
1.4M

Price performance

GPCR price history

1M range · 19 trading sessions · Daily adjusted prices

GPCR closed at $41.23 after 19 trading sessions, down 24.63% for the selected period.

Last close
$41.23
Period change
-24.63%
Period low
$40.38
Period high
$54.70
Daily close
View OHLC price history
GPCR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$41.23$44.94$40.49$41.231.56M
Sep 8, 2026$46.84$47.375$40.26$40.383.42M
Sep 4, 2026$47.26$48.0552$46.73$47.34281.71K
Sep 3, 2026$48.21$48.25$46.37$47.34621.49K
Sep 2, 2026$47.76$48.64$46.07$47.801.06M
Sep 1, 2026$46.02$48.03$45.58$47.13816.63K
Aug 31, 2026$47.08$47.375$45.10$45.911.39M
Aug 28, 2026$48.93$49.20$46.96$47.37601.77K
Aug 27, 2026$49.61$49.81$48.50$49.22318.92K
Aug 26, 2026$49.75$50.065$48.45$49.35937.16K
Aug 25, 2026$49.65$51.02$49.37$49.92463.89K
Aug 24, 2026$48.61$49.33$47.62$49.01822.25K
Aug 21, 2026$50.70$51.11$49.01$49.09592.57K
Aug 20, 2026$54.15$54.60$50.33$50.521.43M
Aug 19, 2026$54.30$55.35$52.40$54.13710.06K
Aug 18, 2026$53.70$55.60$52.5801$53.53687.4K
Aug 17, 2026$54.00$54.655$53.00$53.76305.44K
Aug 14, 2026$54.61$54.99$52.81$54.51555.89K
Aug 13, 2026$53.91$55.00$52.57$54.70444.16K

Latest GPCR news

The latest Smart Investors Daily articles mentioning GPCR.

Stock researchCompany · Overview

GPCR research

Overview

Company profile and research snapshot.

Company profile

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$91.67
Implied upside
—
Analysts
—
GPCR recent ratings
DateFirmRatingTarget
Sep 9, 2026CitizensMarket Outperform—
Aug 7, 2026CitigroupBuy—
Aug 7, 2026CitizensMarket Outperform—
Jun 11, 2026HC Wainwright & Co.Buy—
Apr 27, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September: 2026 Cantor Global Healthcare ConferenceDate: Thursday, September 10Format: Fireside chat and 1x1 meetingsTime: 3:55 – 4:25 PM EDTLocation: New York, NY

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By